0000950170-25-114421.txt : 20250912 0000950170-25-114421.hdr.sgml : 20250912 20250912120030 ACCESSION NUMBER: 0000950170-25-114421 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20250910 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20250912 DATE AS OF CHANGE: 20250912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Longevity Health Holdings, Inc. CENTRAL INDEX KEY: 0001842939 STANDARD INDUSTRIAL CLASSIFICATION: SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 861645738 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40228 FILM NUMBER: 251310523 BUSINESS ADDRESS: STREET 1: 2403 SIDNEY STREET, SUITE 300 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: 412-894-8248 MAIL ADDRESS: STREET 1: 2403 SIDNEY STREET, SUITE 300 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER COMPANY: FORMER CONFORMED NAME: Carmell Corp DATE OF NAME CHANGE: 20230801 FORMER COMPANY: FORMER CONFORMED NAME: Carmell Therapeutics Corp DATE OF NAME CHANGE: 20230727 FORMER COMPANY: FORMER CONFORMED NAME: ALPHA HEALTHCARE ACQUISITION CORP III DATE OF NAME CHANGE: 20210127 8-K 1 xage-20250910.htm 8-K 8-K
0001842939falseNONENONE00018429392025-09-102025-09-100001842939us-gaap:CommonStockMember2025-09-102025-09-100001842939us-gaap:WarrantMember2025-09-102025-09-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2025

 

 

Longevity Health Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40228

86-1645738

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2403 Sidney Street, Suite 300

 

Pittsburgh, Pennsylvania

 

15203

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 412 894-8248

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered
(1)

Common Stock, par value $0.0001 per share

 

XAGE

 

N/A

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $345.00

 

XAGEW

 

N/A

(1)
On September 12, 2025, Longevity Health Holdings, Inc.’s securities were no longer traded on the Nasdaq Capital Market and began trading on the OTC marketplace.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 10, 2025, Longevity Health Holdings, Inc., a Delaware corporation (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had not cured the previously reported deficiency with respect to Nasdaq Listing Rule 5550(b)(2) and as a result, the Panel determined to delist the Company’s securities from the Nasdaq Capital Market at the open of trading on September 12, 2025. The Company’s common stock and warrants began trading publicly on the over-the-counter markets operated by OTC Markets Group, Inc. (“OTC”) at the open of trading on September 12, 2025.

The transition to the OTC marketplace is not expected to affect the Company’s operations. The Company will continue to file periodic and other required reports pursuant to the Securities Exchange Act of 1934, as amended, with the U.S. Securities and Exchange Commission (the “SEC”). The Company believes that the OTC marketplace will continue to provide liquidity for stockholders during this transitional period.

Notwithstanding the delisting of the Company’s securities from Nasdaq, it remains the intention of the Company to continue to pursue the previously disclosed merger with True Health Inc., as well as the listing of the combined company’s securities on Nasdaq.

Forward-Looking Statements

This Current Report contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this Current Report, the Company cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which the Company cannot be certain. Forward-looking statements in this Current Report include, but are not limited to, statements regarding the impact of the delisting on continued Company operations, expectations of trading on the OTC marketplace, expectations regarding the proposed merger with True Health Inc. and the Company’s ability to regain listing of its securities on a national securities exchange in the future. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2025, and in the Company’s other reports filed with the SEC. Most of these factors are outside of the Company’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this Current Report.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

LONGEVITY HEALTH HOLDINGS, INC.

 

 

 

 

Date:

September 12, 2025

By:

/s/ Rajiv Shukla

 

 

 

Rajiv Shukla
Chief Executive Officer

 


EX-101.SCH 2 xage-20250910.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Common Stock [Member] Class of Stock [Axis] Class of Stock [Domain] Warrant [Member] XML 4 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Document And Entity Information
Sep. 10, 2025
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 10, 2025
Entity Registrant Name Longevity Health Holdings, Inc.
Entity Central Index Key 0001842939
Entity Emerging Growth Company true
Entity File Number 001-40228
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 86-1645738
Entity Address, Address Line One 2403 Sidney Street, Suite 300
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15203
City Area Code 412
Local Phone Number 894-8248
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol XAGE
Security Exchange Name NONE
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $345.00
Trading Symbol XAGEW
Security Exchange Name NONE
XML 5 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 6 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports xage-20250910.htm xage-20250910.xsd http://xbrl.sec.gov/dei/2025 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xage-20250910.htm": { "nsprefix": "xage", "nsuri": "http://www.healthxage.com/20250910", "dts": { "inline": { "local": [ "xage-20250910.htm" ] }, "schema": { "local": [ "xage-20250910.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 26 }, "report": { "R1": { "role": "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ce6e593f-618f-42de-ad06-3b0a9270b17d", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "h2", "div", "body", "html" ], "reportCount": 1, "baseRef": "xage-20250910.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ce6e593f-618f-42de-ad06-3b0a9270b17d", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "h2", "div", "body", "html" ], "reportCount": 1, "baseRef": "xage-20250910.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://www.healthxage.com/20250910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 12 0000950170-25-114421-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-114421-xbrl.zip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xage-20250910_htm.xml IDEA: XBRL DOCUMENT 0001842939 2025-09-10 2025-09-10 0001842939 us-gaap:CommonStockMember 2025-09-10 2025-09-10 0001842939 us-gaap:WarrantMember 2025-09-10 2025-09-10 0001842939 false NONE NONE 8-K 2025-09-10 Longevity Health Holdings, Inc. DE 001-40228 86-1645738 2403 Sidney Street, Suite 300 Pittsburgh PA 15203 412 894-8248 true false false false Common Stock, par value $0.0001 per share XAGE Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $345.00 XAGEW true false